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Dementia with Lewy bodies
A B S T R A C T
Gaucher disease, the most common lysosomal storage disease, is caused by a recessively inherited
deﬁciency in glucocerebrosidase and subsequent accumulation of toxic lipid substrates. Heterozygous
mutations in the lysosomal glucocerebrosidase gene (GBA1) have recently been recognized as the highest
genetic risk factor for the development of a-synuclein aggregation disorders (‘‘synucleinopathies’’),
including Parkinson’s disease (PD) and dementia with Lewy bodies (DLB). Despite the wealth of
experimental, clinical and genetic evidence that supports the association between mutant genotypes
and synucleinopathy risk, the precise mechanisms by which GBA1 mutations lead to PD and DLB remain
unclear. Decreased glucocerebrosidase activity has been demonstrated to promote a-synuclein
misprocessing. Furthermore, aberrant a-synuclein species have been reported to downregulate
glucocerebrosidase activity, which further contributes to disease progression. In this review, we
summarize the recent ﬁndings that highlight the complexity of this pathogenetic link and how several
pathways that connect glucocerebrosidase insufﬁciency with a-synuclein misprocessing have emerged
as potential therapeutic targets. From a translational perspective, we discuss how various therapeutic
approaches to lysosomal dysfunction have been explored for the treatment of GBA1-related
synucleinopathies, and potentially, for non-GBA1-associated neurodegenerative diseases. In summary,
the link between GBA1 and synucleinopathies has become the paradigm of how the study of a rare
lysosomal disease can transform the understanding of the etiopathology, and hopefully the treatment, of
a more prevalent and multifactorial disorder.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Abbreviations: AAV, adeno-associated virus; CNS, central nervous system; DLB, dementia with Lewy bodies; ERAD, endoplasmic reticulum associated-degradation; ERT,
enzyme replacement therapy; FDA, Food and Drug Administration; GBA1, lysosomal glucocerebrosidase gene; GBA2, cytosolic glucocerebrosidase gene; HDAC, histone
deacetylase; iPSC, induced pluripotent stem cells; Lamp-2a, lysosomal-associated membrane protein 2a; LRRK2, leucine-rich repeat kinase 2; PCT, pharmacological
chaperone therapy; PD, Parkinson’s disease; RIPK3, receptor-interacting serine–threonine kinase 3; SNCA, a-synuclein gene; SRT, substrate reduction therapy; TFEB,
Contents lists available at ScienceDirect
Progress in Neurobiology
jo u rn al ho m epag e: ww w.els evier . c om / lo cat e/pn eu ro b iotranscription factor EB; VPS35, vacuolar protein sorting 35.
* Corresponding author. Tel.: +1 508 270 2089; fax: +1 508 271 4776.
E-mail address: pablo.sardi@genzyme.com (S.P. Sardi).
1 These authors are employees of Genzyme, a Sanoﬁ Company.
http://dx.doi.org/10.1016/j.pneurobio.2014.12.001
0301-0082/ 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
S.P. Sardi et al. / Progress in Neurobiology 125 (2015) 47–62486. A chronic vicious cycle: a-synuclein effects on glucocerebrosidase. Relevance for sporadic forms of PD . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
7. Potential Gaucher targets as therapeutic approaches for Gaucher-associated PD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
7.1. Glucocerebrosidase augmentation as a therapeutic approach for Gaucher-associated PD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
7.1.1. Direct enzyme augmentation via enzyme replacement therapy (ERT) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
7.1.2. Glucocerebrosidase augmentation via gene delivery . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
7.1.3. Pharmacological chaperone therapy (PCT) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
7.1.4. Alternative approaches to increase lysosomal glucocerebrosidase . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56
7.2. Substrate reduction therapy (SRT) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57
7.3. Necroptosis regulation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57
8. Concluding remarks . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57
Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 581. Gaucher disease: a rare lysosomal storage disorder
Gaucher disease is the most common lysosomal storage
disease and affects approximately 6000 individuals in the U.S.
This disease was ﬁrst described by Phillipe Gaucher in his
doctoral thesis in 1882 (Gaucher, 1882). Dr. Gaucher described a
patient who presented with splenomegaly as a result of an
increased size of the splenic cells. The enlarged cells (now called
‘‘Gaucher cells’’) and an enlarged spleen have become signs of the
disease. A succession of scientiﬁc breakthroughs occurred over
the following century to ultimately achieve a Food and Drug
Administration (FDA)-approved therapy for Gaucher disease in
1991 (Grabowski, 2008).
Gaucher disease is caused by biallelic (homozygous or
compound heterozygous) mutations in the glucocerebrosidase
(GBA1, OMIM 606463) gene (Brady et al., 1966). The GBA1 gene is
located in a gene-rich region on chromosome 1q21 spanning 7.6 kb
and including 11 exons. A highly homologous pseudogene is
located 16 kb downstream and presents challenges for the
molecular analysis of GBA1 (Winﬁeld et al., 1997). Two in-frame
ATG translational initiation sites are found in the GBA1 gene open
reading frame and both give rise to active lysosomal protein (Sorge
et al., 1987). Glucocerebrosidase (EC 3.2.1.45) is a 497 amino acid
protein of approximately 62 kDa that hydrolyses the b-glucosyl
linkage of glucosylceramide and other glycolipids in lysosomes.
Glucocerebrosidase requires the coordinated action of saposin C
and negatively-charged lipids for maximal activity (Grabowski,
2008). Lysosomal trafﬁcking of glucocerebrosidase involves a
speciﬁc binding partner, lysosomal integral membrane protein-2
(Limp-2) for ER maturation and correct sorting to the lysosomes
(Reczek et al., 2007) through a highly regulated mechanism (Jovic
et al., 2012). To date, approximately 300 different mutations have
been identiﬁed in GBA1, including point mutations, frameshift
mutations, splice-site alterations, and recombinant alleles that
encompass segments of a neighboring pseudogene sequence. The
glucocerebrosidase deﬁciency in Gaucher patients promotes
widespread accumulation of substrate glycosphingolipids in
various organs, including the brain. Although GBA1 mutations
are typically associated with glucocerebrosidase activity reduc-
tion, the exact pathogenic mechanism of Gaucher disease remains
unknown. Experimental evidence indicates that reduced glucocer-
ebrosidase activity plays a major role in the pathogenic mecha-
nism. Nevertheless, various alternative mechanisms appear to
contribute to the disease presentation, including the misproces-
sing of the enzyme into the lysosome and an increase in
endoplasmic reticulum associated-degradation (ERAD) stress.
Furthermore, differing clinical presentations in patients and even
siblings who share the same genotype suggest a role for disease
modiﬁers (Cox, 2001; Grabowski, 2008).
Gaucher disease displays a wide spectrum of clinical and
pathological features in humans; thus, it has been subclassiﬁed
according to the involvement of the central nervous system (CNS)structures. The excess accumulation of glucosylceramide in
macrophages is the main manifestation in the visceral organs
of affected individuals. The lipid accumulation can subsequently
lead to hepatosplenomegaly, anemia and thrombocytopenia,
bone involvement, and, other less frequent unpredictable clinical
manifestations (Grabowski, 2008). These visceral manifestations
are common to all variants of Gaucher’s disease, but categorical
differentiation into neuronopathic (type-2 and type-3) and non-
neuronopathic (type-1) variants serves useful clinical purposes.
Because of the primary visceral macrophage involvement in type-
1 Gaucher disease and the intrinsic difﬁculties traversing the
blood–brain barrier to access the CNS, this variant was the initial
focus for the development of enzyme replacement therapies.
Although, class 1 Gaucher disease was historically classiﬁed by
the lack of neurological manifestations, a signiﬁcant number of
patients with type-1 Gaucher disease experience parkinsonism
contesting the current classiﬁcation of Gaucher disease, and
suggesting that the three forms of Gaucher disease each involve a
different proﬁle of neurological manifestations (Beavan and
Schapira, 2013; Grabowski, 2008; Neudorfer et al., 1996;
Sidransky and Lopez, 2012).
Two types of therapies are approved for the treatment of the
visceral manifestations of Gaucher disease. Enzyme replacement
therapy, through the systemic administration of glycan-modiﬁed
recombinant glucocerebrosidase, can effectively treat the viscer-
al and hematological manifestations of Gaucher disease (variant
1) (Barton et al., 1991). However, this form of enzyme
replacement therapy has no effect on CNS pathology in variants
2 and 3 because the recombinant enzyme is unable to traverse
the blood brain barrier. An alternative therapeutic approach for
Gaucher disease that is less widely used is substrate reduction
therapy. This approach inhibits glucosylceramide synthase,
thereby reducing the synthesis of its substrate, glucosylceramide,
to balance production with the impaired rate of degradation (Cox
et al., 2000). To date, treatment with the approved therapies for
Gaucher disease (i.e., Imiglucerase, Velaglucerase or Miglustat)
has not demonstrated effects on the progression of parkinsonism
in patients who present with Gaucher and Parkinson’s disease
(PD) (Bembi et al., 2003; Kraoua et al., 2011; Rosenbloom et al.,
2011).
Twenty years ago, the ﬁrst successful enzyme replacement
therapy was developed for treating Gaucher disease, a monogenic
mechanistically ‘‘simple’’ disorder. The recent and unanticipated
discovery of a genetic link between Gaucher disease and PD has
opened new avenues to study this devastating neurodegenerative
disease. The basic and clinical expertise accumulated for the rare
disease is helping shed light on the development of therapeutics
for more common and complex sporadic forms of disease. The
focus of this review is to provide an update on the current
understanding of the clinical and mechanistic aspects of this
genetic interaction and the various therapeutic approaches under
consideration.
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PD is the second most common neurodegenerative disorder
after Alzheimer’s disease affecting more than 7 M patients
worldwide. The incidence of PD rises sharply after the ﬁfth
decade. PD affects approximately 1–2% of individuals over the age
of 65 and its prevalence increases to approximately 4% in those
above 85 years. As these demographic age groups are growing
rapidly due to general aging of the population and increasing
lifespans, neurodegenerative diseases will represent an ever-
growing social and economic burden (Schlossmacher, 2007).
Initially described by James Parkinson in 1817 (Parkinson,
1817), sporadic PD patients present with the cardinal motor
symptom of bradykinesia and one or several of the following
symptoms: resting tremor, rigidity, and postural instability
(Schlossmacher, 2007). Despite intense research, the causes of
PD are poorly understood, and therapy remains primarily focused
on symptoms with no intervention in the disease-causing
processes (Goedert et al., 2013). Apart from the motor impairment,
PD is associated with a large variety of non-motor symptoms,
which substantially erode the quality of life, reduce life expectancy
and often respond minimally or not at all to the current therapies
(Berg et al., 2013; Chaudhuri and Schapira, 2009).
The scientiﬁc view on PD etiology has dramatically changed
over the last two decades. Numerous etiologies can lead to
parkinsonism and only rare cases can be explained by a single
genetic or environmental cause (Klein and Schlossmacher, 2007).
Initially thought to be an exclusively sporadic disorder, the
association between mutations in the a-synuclein gene (SNCA) and
familial forms of PD was initially received with skepticism
(Polymeropoulos et al., 1997). Since then, multiple studies have
conﬁrmed that missense and gene dosage SNCA mutations can
cause autosomal dominant familial PD (Farrer, 2006). In addition,
multiple independent studies have identiﬁed and validated a
number of genes associated with increased risk for PD (Lill et al.,
2012; Nalls et al., 2014). These studies point at some common
pathways that might be disrupted in affected neurons, such as
protein trafﬁcking and maturation, mitochondrial turnover or
endosome-lysosomal function (Bonifati, 2014; Corti et al., 2011;
Farrer, 2006). Apart from these rare forms, a combination of
genetic and environmental factors are thought to contribute in the
majority of parkinsonism cases. PD is considered a complex
disease, with a multifactorial etiology that involves the compli-
cated and mostly elusive interaction between an aging brain and
several susceptibility genes and environmental risk factors (Klein
and Schlossmacher, 2007).
The pathological hallmark of PD is the progressive degenera-
tion of dopaminergic neurons in the substantia nigra; this
degeneration is accompanied by the accumulation of eosinophilic
intracytoplasmic protein inclusions referred to as Lewy bodies
and Lewy neurites, which primarily consist of a-synuclein
(Spillantini et al., 1997). a-Synuclein pathology distribution
correlates with the clinical progression of synucleinopathies
(Braak and Braak, 2000). a-Synuclein is a 140 amino acid protein
that is highly expressed in neurons, particularly in pre-synaptic
terminals where it exists in an equilibrium between a soluble and
a membrane-bound state (Burre et al., 2014). The precise function
of a-synuclein is not completely understood. Experimental
evidence indicates that it plays a key role in the regulation of
synaptic vesicle clustering and neurotransmitter release (Bendor
et al., 2013; Burre et al., 2014).
The general consensus in the ﬁeld is that aggregation is the
main pathogenic feature of a-synuclein. The close association
between a-synuclein aggregation and neurodegenerative pheno-
types in human patients and animal models and the fact thataccelerated aggregation is a common outcome of most a-synuclein
mutations underlines the relevance of abnormal aggregation of
this protein in the pathogenesis of the synucleinopathies (Stefanis,
2012; Vekrellis et al., 2011). In addition, toxicity is prevented in
variants lacking the ability to form aggregates and agents that
prevent the formation of aggregated species confer protection to
cellular models overexpressing a-synuclein (Lashuel et al., 2013;
Stefanis, 2012). There is less agreement as to which particular
species are pathogenic (Lashuel et al., 2013). It has recently been
proposed that a-synuclein might occur physiologically as helically
folded tetramers that resist aggregation (Bartels et al., 2011; Wang
et al., 2011). Under pathological conditions, a-synuclein homeo-
stasis can be disturbed, leading to the formation of aggregates via
various forms of potentially toxic oligomeric intermediates
(Bartels et al., 2011). a-Synuclein accumulation has been proposed
to exert toxic effects through a variety of mechanisms, including a
blockade of chaperone-mediated autophagy, an impairment of
proteasomal degradation and an increase in endoplasmic reticu-
lum stress (Goedert et al., 2013). Recent work has also provided
evidence that misfolded ﬁbrillar forms of a-synuclein self-
propagate and spread between interconnected CNS regions.
Host-to-graft propagation of a-synuclein-positive Lewy-like
pathology was observed in long-term mesencephalic transplants
in PD (Kordower et al., 2008; Li et al., 2008). These results provided
a working hypothesis to account for the highly predictable pattern
of aggregated a-synuclein spreading from the lower brainstem and
olfactory bulb into the limbic system and, eventually, to the
neocortex (Braak and Braak, 2000) and suggested that a mecha-
nism involving cell-to-cell transmission of pathological proteins
contributes to disease progression, similar to the one observed in
prion diseases (Desplats et al., 2009; Hansen et al., 2011; Luk et al.,
2012, 2009).
3. Gaucher mutations: a common genetic risk for
synucleinopathies
The most common genetic risk factor for PD was discovered
from an unexpected ﬁnding in genetics clinics during studies of
patients with Gaucher disease. Initial clinical studies suggested the
increased occurrence of parkinsonism in Gaucher disease patients
and their obligate carrier family members (Goker-Alpan et al.,
2004; Neudorfer et al., 1996). This initial suggestion was validated
by a large collaborative group that analyzed selected GBA1
mutations in more than 5000 PD patients and healthy controls
without family history of PD and sequenced the entire coding
region in a subset of subjects (Sidransky et al., 2009). These
observations have now been substantiated by multiple genetic
studies demonstrating an increased frequency of mutations in
GBA1 in patients with PD and dementia with Lewy bodies (DLB)
(Beavan and Schapira, 2013). Heterozygote carriers of mutations in
the GBA1 gene have an increased frequency of PD, and
approximately 5–10% of sporadic PD patients have GBA1 muta-
tions, which conﬁrm mutations in this gene as the most important
genetic predisposing risk factor for PD identiﬁed to date (Beavan
and Schapira, 2013; Sidransky et al., 2009).
Initial large genome-wide studies on PD patients failed to
identify GBA1 as a susceptibility gene. These studies sought to
determine common variants and therefore missed the increased
frequency of numerous rare GBA1 variants with low penetrance
and those that occur on different haplotypes (Rogaeva and Hardy,
2008). The glucocerebrosidase story is now considered a paradigm
of ‘‘how an important risk factor for a complex disease can evade
detection by systematic analysis; it only came into the radar because of
astute clinical observations’’ (Rogaeva and Hardy, 2008). Subse-
quent genome-wide association studies that speciﬁcally examined
GBA1 variants conﬁrmed the glucocerebrosidase locus as a risk
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phisms in the gene or mapping the identical-by-descent segments
(Do et al., 2011; Liu et al., 2011; Nalls et al., 2014; Vacic et al., 2014).
The frequency and distribution of GBA1 mutations vary among
populations, hindering comparisons between different patient
series. Carrier frequency is quite high among Ashkenazi Jews
(about 1 person in 14), and N370S accounts for 70% of the mutant
alleles in this population (Beutler and Gelbart, 1993; Horowitz
et al., 1993). The carrier frequency in other ethnic groups is less
than 1%, with a vast range of GBA1 mutations reported (Horowitz
et al., 1993; Sidransky et al., 2009). Regardless of the populations
considered, GBA1 mutations are 5–7 times more frequent in PD
patients than controls (Alcalay et al., 2014; Beavan and Schapira,
2013; Sidransky et al., 2009).
To date, the carrier status of a heterozygous GBA1 mutation is
considered the most common genetic risk factor for an a-synuclein
aggregation-associated disorder in the brain (‘‘synucleinopathy’’).
Abnormal processing and accumulation of a-synuclein, which
leads to Lewy body and Lewy neurite formation, are the major
characteristics of these incurable diseases (Goedert et al., 2013).
Intriguingly, the neuropathological evaluation of brains from select
Gaucher disease patients with parkinsonism and PD subjects who
carry GBA1 mutations have revealed classical a-synuclein-positive,
ubiquitinated Lewy inclusions (Neumann et al., 2009; Wong et al.,
2004). Most inclusions exhibited glucocerebrosidase immunoﬂu-
orescence in the brains from GBA1–mutation carriers (Goker-Alpan
et al., 2010), which suggests a pathophysiological link between
mutant glucocerebrosidase expression and a-synuclein metabo-
lism. Notably, GBA1 mutation status has no reported effect on
multiple system atrophy (MSA), a progressive neurodegenerative
disorder characterized by a-synuclein deposits in oligodendroglial
cytoplasmic inclusions (Goker-Alpan et al., 2006; Segarane et al.,
2009; Srulijes et al., 2013), which might imply different mecha-
nisms for a-synuclein accumulation in neuronal and glial cells.
Evaluation of larger cohorts of MSA patients will be required to
conﬁrm the lack of association between GBA1 mutation status and
diseases with oligodendroglial a-synuclein inclusions. Lastly, two
studies have now shown increased a-synuclein oligomerization in
plasma and red blood cells from patients with GBA1 mutations
(Argyriou et al., 2012; Pchelina et al., 2014). These ﬁndings will
need to be conﬁrmed in larger studies to understand the predictive
value of these a-synuclein species for identiﬁcation of individuals
at risk of developing PD.
Further evidence for the role of glucocerebrosidase in synu-
cleinopathies was revealed in genetic studies that demonstrated
SCARB2 gene polymorphisms are associated with PD and DLB (Bras
et al., 2014; Do et al., 2011; Hopfner et al., 2013; Michelakakis et al.,
2012). The SCARB2 gene encodes Limp-2, a protein that is critical
for glucocerebrosidase transport to the lysosome (Reczek et al.,
2007) and has also been shown to regulate glucocerebrosidase
enzymatic activity (Rothaug et al., 2014). Correspondingly, Limp-2
knockout mice have recently been shown to present a-synuclein
accumulation in the CNS (Rothaug et al., 2014).
Clinical and genetic studies suggest a gene dosage effect in the
association between GBA1 mutations and the development of
synucleinopathies. The odds ratio of harboring severe heterozy-
gote GBA1 mutations (i.e., IVS 2 + 1, 84GG, D409H) was 13.6
compared to an odds ratio of only 2.2 for the milder GBA1
mutations such as N370S (Gan-Or et al., 2008). In line with these
data, carriers of severe GBA1 mutations had a substantially
decreased age at PD onset, compared to carriers of mild mutations,
while patients homozygous or compound heterozygous for GBA1
mutations had the earliest age at onset (Gan-Or et al., 2008). The
GBA1 gene dosage effect on the onset or age-speciﬁc risk for PD has
been conﬁrmed by several independent reports (Alcalay et al.,
2014; Barrett et al., 2013; Becker et al., 2013; Bultron et al., 2010;Nichols et al., 2009; Sidransky et al., 2009). For example, the age-
speciﬁc risk for PD among Ashkenazi Jewish individuals at 70
years-old was 0.7% for non-mutation carriers; 3.5% for carriers of
the GBA1 N370S ‘‘mild’’ mutation; 5.2% for obligate GBA1 carriers
and 9.1% for patients with Gaucher disease (i.e. GBA1 homozygotes
or compound heterozygotes) (Alcalay et al., 2014). However, it is
important to remark that the vast majority of GBA1 carriers and
individuals with homozygous or compound heterozygous GBA1
mutations will never develop PD (Alcalay et al., 2014). It is likely
that additional genetic modiﬁers and environmental factors
inﬂuence the disease risk. As more is known about the
pathophysiological mechanisms underlying GBA1-associated par-
kinsonism and as potential neuroprotective drugs become
available, early identiﬁcation of those at highest risk will be critical.
4. Clinical features of Gaucher-related PD
The general clinical phenotype of PD patients with GBA1
mutations is largely indistinguishable from sporadic PD; however,
these patients present increased frequencies and severities of
motor and non-motor symptoms that substantially erode their
quality of life (Beavan and Schapira, 2013). Genetic variation in
GBA1 has emerged as a signiﬁcant feature impacting the natural
history of PD. Patients who carry GBA1 mutations present a higher
prevalence and severity of bradykinesia, motor complications,
hyposmia, autonomic impairment, sexual dysfunction, hallucina-
tions, cognitive decline, depression and anxiety (Alcalay et al.,
2012; Beavan and Schapira, 2013; Brockmann et al., 2011; Lesage
et al., 2010; Li et al., 2014; McNeill et al., 2012; Wang et al., 2014;
Winder-Rhodes et al., 2013; Zokaei et al., 2014). Because of the
increased rate of clinical decline, patients with GBA1 mutations
often initiate therapies earlier compared with non-mutation
carriers (Angeli et al., 2013; Barrett et al., 2014).
Cognitive impairment is one of the most disabling non-motor
complications of PD (Alcalay et al., 2012). Post-mortem
evaluation of brains from Gaucher patients with parkinsonism
and PD subjects who carried GBA1 mutations have revealed a
widespread diffuse hippocampal and neocortical distribution of
Lewy bodies, which suggests Lewy body neuropathology may be
more extensive in GBA1 carriers and may be associated with
cognitive impairment (Clark et al., 2009; Hall et al., 2014;
Neumann et al., 2009; Wong et al., 2004). These ﬁndings are in
agreement with a study demonstrating that subjects with PD and
GBA1 mutations present reduced resting regional cerebral blood
ﬂow in a pattern characteristic of diffuse Lewy body disease
(Goker-Alpan et al., 2012). Correspondingly, a mouse model of
Gaucher disease has been demonstrated to exhibit memory
deﬁcits, as well as progressive accumulation of ubiquitinated a-
synuclein aggregates in hippocampal and cortical neurons (Sardi
et al., 2011).
Increased cognitive decline has reportedly been the most
notable difference observed between PD patients who carry
mutant compared with normal GBA1 alleles. In a recent
longitudinal study in unselected cases with PD, heterozygote
GBA1 mutation carriers showed a signiﬁcantly greater risk for
progression to dementia (Winder-Rhodes et al., 2013). Multiple
independent studies have conﬁrmed that individuals who carry
mutations in GBA1 have a higher incidence of cognitive
impairment and dementia (Agosta et al., 2013; Chahine et al.,
2013; Clark et al., 2009; Neumann et al., 2009; Seto-Salvia et al.,
2012). In addition, the risk of developing DLB is reportedly three-
fold higher than PD, underlying the relevance of GBA1 mutations
on the cognitive function (Asselta et al., 2014; Nalls et al., 2013).
Indeed, mutations in GBA1 are now recognized as an independent
risk factor for the development of cognitive impairment in PD
patients (Alcalay et al., 2012).
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levels of plasma ceramide and glucosylceramide were associated
with cognitive impairment, further implicating the glucocerebro-
sidase pathway in the development of dementia (Mielke et al.,
2013). These ﬁndings will need to be conﬁrmed by large
longitudinal studies including normal controls and GBA1 mutation
status to understand the predictive value of these lipids and their
ability to identify individuals at risk of progressive cognitive
impairment.
5. Role of glucocerebrosidase in the development of
synucleinopathies
5.1. Reduced glucocerebrosidase increases a-synuclein levels
The role of GBA1 mutations in the pathogenesis of synuclei-
nopathies is not fully understood, but experimental data indicate
that there is a direct relationship between glucocerebrosidase
activity and a-synuclein (Fig. 1). Both mutant GBA1-mediated loss-
of-function and toxic gain-of-function hypotheses have been
proposed. Importantly, these two hypotheses are not mutually
exclusive, and each scenario is supported by clinical, genetic and
experimental evidence (Cullen et al., 2011; Sardi et al., 2011, 2012;
Velayati et al., 2010). It is conceivable that in aged humans, GBA1Fig. 1. Potential roles of glucocerebrosidase in the development of synucleinopath
autophagosomal function, which would result in increased levels of a-synuclein and decr
membrane composition and trigger a-synuclein seeding. (C) Decreased GCase and/or the 
and lead to a-synuclein accumulation and activation of ER stress signals. (D) Direct bind
decrease the hydrolase activity. (E) Decreased GCase may increase the disease progress
Hypothetical model for a-synuclein aggregation. Native a-synuclein can undergo misfo
continues to form larger amyloid ﬁbrils and subsequent Lewy bodies. See text for detaheterozygosity promotes a-synuclein misprocessing through two
mechanisms, namely, a gain of function effect, which is mediated
by its encoded mutant glycoprotein and can be further exacerbated
by reduced glucocerebrosidase enzyme activity through a loss of
function effect. Thus, both mechanisms may modulate PD
susceptibility and lower the observed age of disease onset (Clark
et al., 2007; Nichols et al., 2009).
The signiﬁcance of the glucocerebrosidase activity is under-
scored by the fact that GBA1-null (e.g., 84GG or IVS2 + 1G > A)
mutations in humans are associated with a higher risk of the
development of synucleinopathies (Gan-Or et al., 2008; Sidransky
et al., 2009). In support of the loss of function hypothesis,
glucocerebrosidase activity reduction via pharmacological inhibi-
tors or mRNA knock-down strategies can affect a-synuclein
homeostasis in cultured cells (Manning-Bog et al., 2009; Mazzulli
et al., 2011). In contrast, the effects of GBA1 mutations independent
of activity reduction are more difﬁcult to assess because the
presence of mutations generally affects the enzymatic activity. One
study reported that the coexpression of wild-type and mutant
glucocerebrosidase in mesencephalic cells increased a-synuclein
levels with no notable effects on total glucocerebrosidase activity
(Cullen et al., 2011). Similarly, the half-life of human a-synuclein
in cortical neurons from mice expressing one mutant L444P Gba1
and one WT allele was increased by more than 70% compared toies. (A) Decreased glucocerebrosidase activity (GCase) could lead to reduced
eased protein and mitochondrial degradation. (B) Reduction in GCase may alter lipid
presence of GBA1 mutations can overwhelm the ER-associated degradation pathway
ing of a-synuclein to GCase could displace the activator protein saposin C to further
ion via the promotion of cell-to-cell transmission of oligomeric a-synuclein. Inset:
lding under pathological conditions and oligomerize. Toxic oligomeric a-synuclein
ils and references.
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addition, a-synuclein aggregation has been observed in Gba1
heterozygous mice that carry a mutant (D409V) allele (Sardi et al.,
2011).
The effects of glucocerebrosidase activity on a-synuclein
accumulation appear to be cell speciﬁc because a-synuclein
accumulation could not be observed in neuroblastoma cells or
primary rat cortical neurons treated with conduritol-B-epoxide
(Dermentzaki et al., 2013). Similarly, the overexpression of wild-
type glucocerebrosidase in HEK293 cells that expressed A53T a-
synuclein and PC12 cells that expressed wild-type a-synuclein
induced down-regulation of a-synuclein levels (Cullen et al.,
2011). However, this effect was not observed when wild-type
glucocerebrosidase was transiently transfected in MES23.5 cells
that expressed wild-type a-synuclein (Cullen et al., 2011).
Additional evidence for the role of glucocerebrosidase in a-
synuclein homeostasis derives from animal studies. Several
independent groups have now reported the presence of a-
synuclein accumulation in the brains of mouse models of Gaucher
disease carrying different mutations (Cullen et al., 2011; Fishbein
et al., 2014; Ginns et al., 2014; Sardi et al., 2011; Xu et al., 2010,
2014). The initial insult caused by the lipid and a-synuclein
accumulation can then progress to develop secondary neuroin-
ﬂammatory pathology, mitochondrial dysfunction or a more
profound proteinopathy (Ginns et al., 2014; Sardi et al., 2013;
Xu et al., 2014).
Finally, studies have shown that increasing glucocerebrosidase
levels can modulate a-synuclein accumulation. Overexpression of
wild-type glucocerebrosidase in the hippocampus of a mouse
model of Gaucher and synucleinopathy reduced the accumulation
of a-synuclein (Sardi et al., 2011, 2013). Correspondingly,
dopaminergic neurons from induced pluripotent stem cells (iPSC)
generated from patient derived ﬁbroblasts carrying heterozygous
GBA1 mutations (i.e., RecNcil/WT, L444P/WT and N370S/WT)
exhibited increased a-synuclein levels that were normalized in
their isogenic gene-corrected controls (Schondorf et al., 2014).
Recently, iPSC-derived dopamine neurons were generated from
monozygotic twins carrying heterozygous GBA1 N370S mutations
and discordant for PD (Woodard et al., 2014). Cells originating from
both twins showed increased a-synuclein levels that were reduced
by glucocerebrosidase overexpression using a lentiviral vector.
Interestingly, a-synuclein cellular distribution differed between
the twins with more a-synuclein in the neurites of the affected
twin (Woodard et al., 2014). Although the complete mechanistic
picture remains unknown, evidence suggests that glucocerebro-
sidase haploinsufﬁciency as a result of GBA1 mutations can
interfere with a-synuclein processing and contribute to the
pathological accumulation of the protein.
5.2. Glucocerebrosidase deﬁcits and lysosomal dysfunction
Maintaining the ﬁne balance between the synthesis and
degradation of molecules and organelles is critical for cellular
homeostasis and proper cellular function. Neurons are particularly
vulnerable to alterations in the autophagy machinery as evidenced
by the brain sensitivity to mutations in genes involved in the global
lysosomal network (autophagy and endosomal pathway) and in
primary lysosomal disorders (Nixon, 2013). The autolysosomal
pathway plays a central role in the degradation of bulky material,
including misfolded proteins and damaged organelles; mutations
in genes involved in this pathway have increasingly been linked to
the synucleinopathies. The autolysosomal pathway plays a central
role in the degradation of bulky material, including misfolded
proteins and damaged organelles; mutations in genes involved in
this pathway have increasingly been linked to the synucleino-
pathies (Dehay et al., 2013; Tofaris, 2012). Mutations in PINK1(encoding for PTEN-induced putative kinase 1), PARK2 (encoding
for Parkin, an E3 ubiquitin ligase) and ATP13A2 (encoding the
protein ATP13A2, a lysosomal type 5 P-type ATPase) cause
autosomal recessive early-onset parkinsonism. PINK1 and Parkin
play a key role in the maintenance of healthy mitochondria by
participating in lysosome-dependent degradation of damaged
mitochondria through autophagy (Ashraﬁ and Schwarz, 2013).
Mutations in lysosomal membrane protein ATP13A2 cause familial
Kufor–Rakeb syndrome characterized by early onset parkinsonism,
pyramidal degeneration and dementia. These mutations lead to
general lysosomal alterations in patient-derived ﬁbroblasts,
including reduced degradation of lysosomal substrates, and
diminished lysosomal-mediated clearance of autophagosomes
(Dehay et al., 2012; Usenovic et al., 2012). ATP13A2-mediated
lysosomal dysfunction can result in accumulation of a-synuclein
and toxicity in mouse primary cortical neurons (Usenovic et al.,
2012). Mutations in the VPS35 (vacuolar protein sorting 35) and
LRRK2 (encoding the Leucine-rich repeat kinase 2) genes,
associated to autosomal dominant disease, also implicate the
autolysosomal pathway in the pathogenesis of PD. Recent work has
shown that disease-causing mutation in VPS35 restricts autopha-
gosome formation, impairs lysosomal degradation of a-synuclein
and exacerbates neuronal vulnerability to PD-relevant cellular
stress (Miura et al., 2014; Tsika et al., 2014; Zavodszky et al., 2014).
Studies with LRRK2 mutants implicated in autosomal dominant PD
incriminated this kinase in the regulation of both macroautophagy
and chaperone-mediated autophagy (Alegre-Abarrategui et al.,
2009; Orenstein et al., 2013).
Several independent studies have reported autolysosomal
dysfunction caused by glucocerebrosidase insufﬁciency. The
inhibition of glucocerebrosidase activity by pharmacological
inhibitors or mRNA silencing strategies has led to decreased
lysosomal protein turnover and accumulation of lysosomal-
associated membrane protein-1 structures and autophagosomes
per LC3-II buildup in various neuronal cell models (Bae et al., 2014;
Dermentzaki et al., 2013; Gegg et al., 2012; Mazzulli et al., 2011;
Osellame et al., 2013). Autophagy and lysosomal dysfunction have
also been reported in models and tissue samples from subjects
with GBA1-associated PD (Gegg et al., 2012; Schondorf et al., 2014).
In addition, a lack of glucocerebrosidase caused an accumulation of
dysfunctional mitochondria secondary to impaired autophagy and
dysfunctional proteasomal pathways (Cleeter et al., 2013; Osel-
lame et al., 2013).
Normal lysosomal function is critical for the regulation of a-
synuclein homeostasis, as this protein is degraded primarily
through lysosomal autophagic mechanisms (Cuervo et al., 2004)
(Martinez-Vicente and Cuervo, 2007). The primary lysosomal
dysfunction and lipid accumulation caused by decreased gluco-
cerebrosidase activity may subsequently stimulate a-synuclein
accumulation. Importantly, the buildup of a-synuclein would
then propel to further impairment of the lysosomal and
proteosomal degradative machineries (Lindersson et al., 2004;
Martinez-Vicente et al., 2008), thereby leading to a more
generalized dysfunction and increased neuronal vulnerability
to stressors (see Fig. 1).
5.3. Glucocerebrosidase decline and lipid alterations
Membrane lipid interactions with a-synuclein have been
strongly associated with the biological and pathological functions
of a-synuclein. Alterations in membrane lipid composition can
contribute to a-synuclein aggregate seeding (Bendor et al., 2013).
Glucocerebrosidase deﬁcits in Gaucher disease cause marked
glycolipid accumulation. For example, glucosylceramide and
glucosylsphingosine accumulation has been observed in the
CNS of neuropathic Gaucher disease patients with decreased
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Orvisky et al., 2002).
Evidence for glucocerebrosidase substrate accumulation in
whole-brain lysates from animals or patients who carry heterozy-
gous mutations in GBA1 has been elusive (Sardi et al., 2011). A
recent report demonstrated increased glucosylceramide levels in
iPSC-derived dopaminergic-enriched neuronal cultures from GBA1
mutation carriers with parkinsonism after more than 70 days in
vitro (Schondorf et al., 2014). These studies suggest that speciﬁc
cell types present selective vulnerability to lipid pathway
modiﬁcations (Farfel-Becker et al., 2014) and highlight the
difﬁculty in determining lipid alterations in deﬁned cell popula-
tions in brain tissue, where small changes might be concealed by
the contribution of different cell types. In addition, the subcellular
localization of lipids has been reportedly affected by decreased
glucocerebrosidase activity (Hein et al., 2008). These changes in
glycosphingolipids may particularly affect lipid raft function by
interfering with the sorting and trafﬁcking of proteins and lipids
associated with the rafts. Remarkably, a-synuclein is localized to
lipid rafts in neuronal cells (Fortin et al., 2004), and glucosylcer-
amide has been described to directly promote a-synuclein
oligomerization (Mazzulli et al., 2011). Therefore, it is speculated
that lipid changes induced by partial glucocerebrosidase deﬁciency
may alter the interaction between lipid microdomains and a-
synuclein, which might, in turn, lead to synaptic dysfunction and
selective neuronal demise (Farfel-Becker et al., 2014; Ginns et al.,
2014).
A selective reduction in total ceramide but not sphingomyelin
has recently been reported in early stage PD anterior cingulate
cortex (Murphy et al., 2014). Ceramide reduction was observed in
brain regions that accumulate a-synuclein and glucocerebrosidase
deﬁciency. However, these ﬁndings are difﬁcult to associate to the
decrease in glucocerebrosidase activity as no decrease in ceramide
levels are observed in Gaucher disease mouse brains lacking
glucocerebrosidase expression (Farfel-Becker et al., 2014) or in
patients with Gaucher disease (Almeida, 2012). The ceramide
metabolism dysfunction might suggest signiﬁcant changes in
neuronal membrane properties in PD patients (Fabelo et al., 2011).
5.4. Glucocerebrosidase effects on endoplasmic reticulum stress
The accumulation of misfolded proteins in the brain is a salient
feature of PD and other neurodegenerative diseases. To maintain
balanced cell proteostasis, aberrant proteins are turned over via
endoplasmic reticulum-associated degradation (ERAD) through
ubiquitination and proteosomal degradation (Mercado et al.,
2013). The accumulation of misfolded proteins that cannot be
effectively removed by ERAD leads to ER stress and activates the
unfolded protein response that can ultimately elicit apoptosis. ER
stress is thought to play crucial roles in the cellular pathology of
dopaminergic neurons (Mercado et al., 2013).
Under physiological conditions, newly synthesized glucocereb-
rosidase is correctly folded in the endoplasmic reticulum and
glycosylated in the Golgi prior to arrival at the lysosome. In contrast,
mutant glucocerebrosidase can be recognized as misfolded in the ER
and undergo ERAD, cytoplasmic retrotranslocation and ubiquitina-
tion followed by proteasomal degradation (Ron et al., 2010). The
persistent presence of mutant, misfolded glucocerebrosidase
molecules in the ER can eventually lead to ER stress and evoke
the unfolded protein response (Maor et al., 2013). However, acute
inhibition of glucocerebrosidase with the pharmacological inhibitor,
CBE, reportedly stimulated ER stress in neuroblastoma cells, which
indicates enzymatic activity may also play a role independent of the
presence of a pathogenic mutation (Korkotian et al., 1999; Kurzawa-
Akanbi et al., 2012). In addition, a neuropathic Gaucher disease
mouse model that lacks glucocerebrosidase expression in neuronsand macroglia displays neuronal dilations of the ER cisternae at early
stages of storage, which further suggests a role of glucocerebrosidase
activity in ER homeostasis (Farfel-Becker et al., 2014). Therefore, the
predisposition to ER stress in cells that carry glucocerebrosidase
defects might be a combined effect of the presence of mutant protein
and the loss of glucocerebrosidase enzymatic activity.
5.5. Direct interaction between glucocerebrosidase and a-synuclein
Initial immunoﬂuorescence studies on brain tissue samples
from patients with parkinsonism associated with glucocerebrosi-
dase mutations demonstrated that glucocerebrosidase was present
in most Lewy bodies, which indicates glucocerebrosidase can be an
important component of a-synuclein-positive pathological inclu-
sions (Goker-Alpan et al., 2010). Subsequent biochemical studies
have reported a direct physical interaction between glucocereb-
rosidase and a-synuclein under acidic conditions, which mimics
the lysosomal lumen (Yap et al., 2011). The same group later
demonstrated that the membrane-bound a-helical form of a-
synuclein interacted with glucocerebrosidase and inhibited its
hydrolase activity (Yap et al., 2013b) and that the sphingolipid
activator protein saposin C protected glucocerebrosidase from a-
synuclein inhibition by competing for its binding (Yap et al.,
2013a). Accordingly, a-synuclein knockout mice reportedly
Exhibit 35% increase in glucocerebrosidase activity without
affecting the overall level of enzyme (Fishbein et al., 2014),
supporting the in vitro observation of the inhibitory effect of
membrane-bound a-synuclein.
Saposin C is an essential activator of glucocerebrosidase, and
saposin C deﬁciency causes Gaucher disease (Tamargo et al., 2012).
In vivo studies have also revealed saposin C as a modiﬁer of a-
synuclein homeostasis. Mouse models of Gaucher disease that
carry hypomorphic forms of the saposin C precursor prosaposin
present a more aggressive form of Gaucher disease with profound
neurological involvement and deﬁcits in CNS autophagy and
proteostasis, which lead to the accumulation of misfolded proteins,
including a-synuclein (Xu et al., 2014). Taken together, the relief of
a-synuclein-mediated inhibition of glucocerebrosidase activity by
saposin C and the accumulation of a-synuclein in prosaposin
deﬁcient models implicate glucocerebrosidase activity dysfunction
as a critical driver of disease pathogenesis in GBA1-associated
synucleinopathies.
5.6. Glucocerebrosidase affects a-synuclein cell-to-cell transfer
An emerging ﬁeld of study in PD and other neurodegenerative
diseases is the signiﬁcance of cell-to-cell transfer of misfolded
proteins as a mechanism of disease propagation (Goedert et al.,
2013). In the case of synucleinopathies, several independent reports
have demonstrated that a-synuclein aggregates are transmitted
through exocytosis and subsequent endocytosis between neighbor-
ing cells (Lee et al., 2010). Studies have shown that a-synuclein
might be released by exocytosis in a calcium-dependent manner
(Emmanouilidou et al., 2010; Lee et al., 2005). The effects of
glucocerebrosidase deﬁciency on a-synuclein release have not yet
been reported. It is conceivable that glucocerebrosidase depletion
would increase a-synuclein release, as lysosomal impairment
exacerbates this phenomenon (Alvarez-Erviti et al., 2011).
Extracellular a-synuclein has been demonstrated to have
neurotoxic properties and the ability to enhance the aggregation
process of endogenous a-synuclein through a seeding process,
which therefore contributes to the formation of Lewy body-like
inclusions (Hansen et al., 2011; Luk et al., 2009). Although the
intrinsic mechanisms are still under investigation, studies have
demonstrated that endolysosomal dysfunction increases a-synu-
clein uptake (Alvarez-Erviti et al., 2011; Lee et al., 2014). Consistent
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neuronal cell-to-cell transmission of endogenous a-synuclein
upon glucocerebrosidase knock-down using a zinc ﬁnger nuclease
approach (Bae et al., 2014). The in vivo relevance of the pathogenic
a-synuclein transmission was demonstrated by transplanting
normal and GBA1/ SH-SY5Y cells into the hippocampus of
transgenic mice expressing human a-synuclein. Analysis of host-
derived a-synuclein showed increased transmission in grafted
cells lacking glucocerebrosidase compared to controls (Bae et al.,
2014). Interestingly, and in agreement with previous studies (Sardi
et al., 2011), the authors showed that the ectopic expression of
wild-type glucocerebrosidase, but not an activity-deﬁcient mu-
tant, reversed the effects of GBA1 deletion on the propagation of a-
synuclein aggregates, indicating that the hydrolase enzymatic
activity is required for the spread of a-synuclein (Bae et al., 2014).
Collectively, these studies support the notion that the augmenta-
tion of glucocerebrosidase activity might provide a disease
modifying therapy and suggest that restoration of the protein’s
activity may retard the propagation of Lewy pathology, thereby
halting the progression of PD.
6. A chronic vicious cycle: a-synuclein effects on
glucocerebrosidase. Relevance for sporadic forms of PD
The exact molecular mechanisms implicated in the interaction
between GBA1 gene mutations and the increased risk of
synucleinopathies remains unresolved. Importantly, the reciprocal
relationship between a-synuclein and glucocerebrosidase is
increasingly gaining traction. This relationship is particularly
relevant to understand the pathogenic role of glucocerebrosidase
in sporadic forms of the disease in patients with two wild-type
GBA1 alleles. As previously reviewed, several lines of evidence have
demonstrated that a decrease in glucocerebrosidase activity
promotes an increase in a-synuclein levels. Conversely, studies
have also shown that a-synuclein buildup can promote glucocer-
ebrosidase deﬁciency. Overexpression of a-synuclein in neuronal
cells and mouse brain prompted a speciﬁc decrease in glucocer-
ebrosidase activity without affecting other lysosomal enzymes
(Gegg et al., 2012; Mazzulli et al., 2011; Parnetti et al., 2014; Sardi
et al., 2012, 2013; Schondorf et al., 2014; Yap et al., 2013b). The
mechanisms responsible for this inhibitory effect are still under
investigation. Experimental evidence has been put forward
suggesting that a-synuclein might impair ER to Golgi trafﬁcking
of glucocerbrosidase or directly inhibit the enzyme in the
lysosomal compartment (Gegg et al., 2012; Mazzulli et al., 2011;
Sardi et al., 2012, 2013; Yap et al., 2013b). Consistently, the decline
in glucocerebrosidase activity by a-synuclein accumulation was
also described in brain tissues of sporadic PD patients despite
carrying two wild-type GBA1 alleles (Gegg et al., 2012; Parnetti
et al., 2014; Schondorf et al., 2014). The bidirectional effects of a-
synuclein and glucocerebrosidase form a positive feedback loop
that, after a threshold, may lead to a self-propagating disease.
The bidirectional link between a-synuclein and glucocerebro-
sidase activity is also supported by studies in individuals with no
known mutations in GBA1, which suggests the analysis of CSF
glucocerebrosidase activity and the ratio of oligomeric/total a-
synuclein could help to discriminate early stages of PD from
neurological controls (Parnetti et al., 2014). Accordingly, a recent
report has demonstrated that glucocerebrosidase deﬁcits in early
sporadic PD brains from patients carrying wild-type GBA1 are
directly associated with abnormal accumulation of a-synuclein
and substantial alterations in lysosomal autophagy function before
the establishment of neuronal loss (Murphy et al., 2014).
Various pathogenic pathways might conspire to promote a-
synuclein-dependent glucocerebrosidase insufﬁciency (Fig. 1). For
example, the accumulation of a-synuclein has been demonstratedto inhibit lysosomal translocation of newly synthesized proteins,
including glucocerebrosidase (Chung et al., 2013; Cooper et al.,
2006; Mazzulli et al., 2011). Therefore, in sporadic PD cases, if the
delicate balance of a-synuclein homeostasis is disturbed by an
impairment of essential protein turnover pathways, such as the
unfolded protein response, ERAD, autophagy, cell stress or
environmental factors, the increase in a-synuclein levels might
inhibit translocation of glucocerebrosidase from the ER to the
lysosome. The decreased ER trafﬁcking could lead to reduced
glucocerebrosidase activity, which has been observed in the brains
of mice overexpressing a-synuclein and PD patients who carried
normal GBA1 alleles (Gegg et al., 2012; Sardi et al., 2013).
Alternatively, lysosomal glucocerebrosidase activity might be
inhibited by direct a-synuclein interaction as previously described
(Yap et al., 2011). In turn, less lysosomal glucocerebrosidase could
eventually lead to a gradual increase in the glucocerebroside
substrate and subsequent oligomerization and accumulation of a-
synuclein that completes the vicious cycle (Mazzulli et al., 2011).
Mechanistically, positive feedback loops are extremely difﬁcult
to dissect, and the identiﬁcation of the trigger for the cascading
loop is virtually impossible and is not required to halt the chain of
events. In the case of GBA1 mutation carriers, the trigger of the
feedback loop would presumably be the reduced hydrolase
activity. In sporadic patients, the idiopathic accumulation of a-
synuclein might initiate the feedback mechanism, which subse-
quently leads to a decrease in glucocerebrosidase activity and
additional a-synuclein buildup. Regardless of the initial trigger,
glucocerebrosidase augmentation in the CNS has been proposed to
slow disease progression and even reverse several pathological
manifestations of synucleinopathies, independent of the presence
of GBA1 mutations (Bae et al., 2014; Sardi et al., 2011, 2013).
7. Potential Gaucher targets as therapeutic approaches for
Gaucher-associated PD
7.1. Glucocerebrosidase augmentation as a therapeutic approach for
Gaucher-associated PD
There are many challenges that need to be overcome to develop
disease-modifying therapies for PD. The identiﬁcation of GBA1
mutations as the most important risk factor for the development of
synucleinopathies has provided a credentialed target validated
through human genetics and animal experiments (Alcalay et al.,
2012, 2014; Bae et al., 2014; Richter et al., 2014; Sardi et al., 2012,
2013; Schondorf et al., 2014; Sidransky et al., 2009). Animal and
cell culture experiments support the notion that increasing
glucocerebrosidase activity can lower a-synuclein levels and the
associated toxicity (Cullen et al., 2011; Sardi et al., 2011). For
example, CNS augmentation of glucocerebrosidase in a symptom-
atic mouse model of Gaucher-related synucleinopathy has been
demonstrated to reduce the accumulation of a-synuclein aggre-
gates and correct the memory impairment in pre- and post-
symptomatic animals (Sardi et al., 2011, 2013). Consistent with
these results, a recent report has demonstrated that increase in the
hydrolase activity of glucocerebrosidase is required for the
salutary effects as expression of wild-type enzyme, but not a
catalytically-inactive mutant (E235K), rescued the effects of GBA1
deletion on the cell-to-cell transmission of a-synuclein aggregates
(Bae et al., 2014). Hence, it has been proposed that increasing
glucocerebrosidase activity in the CNS may slow disease progres-
sion and ‘‘reverse’’, at least in part, several pathological manifesta-
tions associated with Gaucher-related synucleinopathies. Further
validation for this approach has recently been suggested by a
report describing signiﬁcant reduction in plasma oligomeric
a-synuclein in Gaucher patients receiving glucocerebrosidase
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patients not undergoing treatment (Pchelina et al., 2014).
Because of its involvement in Gaucher disease, there is
considerably more scientiﬁc knowledge and clinical experience
in GBA1 compared with other PD-related genes or potential
therapeutic strategies.
This section focuses only on putative therapeutics that target
the glucocerebrosidase pathway as a disease-modifying approach
for Gaucher-related PD and potentially for sporadic PD. Other
potential disease modifying treatments, including neurorestora-
tion and neuroprotection, with mechanisms of action that do not
directly impact this lysosomal hydrolase pathway are not
discussed here.
7.1.1. Direct enzyme augmentation via enzyme replacement therapy
(ERT)
Gaucher disease is characterized by a deﬁciency of glucocer-
ebrosidase activity and subsequent lysosomal accumulation of
undegraded substrates. Glycosyl-modiﬁed recombinant human
glucocerebrosidase is routinely administered to patients with
Gaucher disease as enzyme replacement therapy (ERT). This
treatment has been demonstrated to stabilize or reverse several
features of Gaucher disease that result from hematologic, visceral,
and skeletal involvement. Since 1992, enzyme replacement with
recombinant glucocerebrosidase has become the standard of care
for patients with non-neuronopathic (type 1) Gaucher disease
(Grabowski et al., 1998; Pastores, 2010). ERT is also given to a
majority of Gaucher disease type 3 patients, as a means of
addressing their systemic symptoms. However, this therapy does
not address the CNS manifestations of the disease because the
recombinant enzyme is unable to traverse the blood–brain barrier
(Pastores, 2010). Brain glucocerebrosidase augmentation has been
proposed as a therapy to address the neurological manifestations
of Gaucher disease types 2 and 3 (Lonser et al., 2007). Preclinical
efforts have been directed at enzyme replacement therapies with
CNS-targeting motifs (Spencer and Verma, 2007; Watts and
Dennis, 2013), as well as direct brain infusions of recombinant
enzyme (Cabrera-Salazar et al., 2010; Ziegler et al., 2011). In
addition, these approaches must demonstrate that therapeutic
levels and widespread brain distribution of the enzyme can be
achieved.
7.1.2. Glucocerebrosidase augmentation via gene delivery
During the previous decade, various gene therapy clinical trials
for PD have been initiated and completed. Both adeno-associated
virus (AAV) and lentivirus vector platforms have been demon-
strated to provide a safe, controlled, highly persistent expression of
biologically active proteins to target structures in the human brain
(Bartus et al., 2014). In addition, preclinical studies have
demonstrated that glucocerebrosidase augmentation via AAV1
can reverse cognitive deﬁcits in a mouse model of Gaucher-related
synucleinopathy and decrease a-synuclein in the A53T-alpha-
synucleinopathy mouse model (Sardi et al., 2013). Importantly, a
widespread increase in glucocerebrosidase activity in the CNS may
be required for clinical translation of the therapeutic beneﬁt.
The development of gene therapy as a therapeutic strategy for
lysosomal storage disorders has also made considerable progress
over the past several years (Cheng, 2014). The premise of gene
therapy for this group of diseases is borne of ﬁndings that genetic
modiﬁcation of a subset of cells can provide a more global beneﬁt
by virtue of the ability of the secreted lysosomal enzymes to effect
cross correction of adjacent and distal cells (Fratantoni et al., 1968).
Although initial indications from these studies are encouraging, it
is evident that second-generation vectors that exhibit a greater
safety proﬁle and transduction activity may be required before this
optimism can be fully realized (Cheng, 2014). Several recentstudies have suggested that some AAV serotypes could achieve
extensive CNS distribution in non-human primates (Passini et al.,
2014; Yang et al., 2014a). However, the optimal serotype, route of
delivery and brain distribution to critical brain regions must be
further investigated prior to the development of glucocerebrosi-
dase gene therapy for conditions requiring widespread distribu-
tion of therapeutic proteins in the CNS, including lysosomal
storage diseases and Gaucher-related PD.
7.1.3. Pharmacological chaperone therapy (PCT)
The use of pharmacological chaperones has also been proposed
for Gaucher disease as an alternative to ERT. Pharmacological
chaperone therapy (PCT) is based on the use of chaperone
molecules that can assist in the folding of the mutated enzyme
in the endoplasmic reticulum and improves their stability and
lysosomal trafﬁcking (Boyd et al., 2013; Trapero and Llebaria,
2013). This approach is mutation speciﬁc and is not amenable to
certain mutations that involve large insertions or deletions,
frameshifts or premature stop codons that lead to no protein
expression. In addition, most pharmacological chaperones that
have been identiﬁed bind to the catalytic site and inhibit the
enzymatic activity, which thus requires chaperone dissociation to
permit substrate hydrolysis. The ﬁrst glucocerebrosidase chaper-
one to undergo clinical trials was isofagomine (i.e., afegostat-
tartrate or AT2101). At low concentrations, isofagomine reportedly
promotes a rise in glucocerebrosidase activity. Isofagomine
binding to nascent enzyme in the ER permits its further maturation
through the ER/Golgi network, thereby reducing the degradation
rate of misfolded glucocerebrosidase and promoting its successful
transfer to the lysosomes (Lieberman et al., 2007). A small trial in
Gaucher patients who used isofagomine lacked adequate clinical
improvement in key outcome measures, and further clinical
development for this indication was discontinued (Boyd et al.,
2013).
The interest in this class of therapeutics might be revitalized as
preclinical studies have reported that glucocerebrosidase chaper-
ones can affect a-synuclein processing. Isofagomine treatment of
PC12 cells overexpressing human a-synuclein and mutant
glucocerebrosidase showed a nonsigniﬁcant trend in reducing
a-synuclein concentrations (Cullen et al., 2011). A more recent
report described that oral administration of isofagomine to a-
synuclein transgenic mice for 4 months increased the brain
glucocerebrosidase activity, improved olfactory deﬁcits in the
buried pellet test and partially recovered motor function using two
different tests to evaluate balance and coordination (Richter et al.,
2014). In addition, histopathological analysis showed that
isofagomine treatment reduced the number of activated microglia
in the substantia nigra and altered the size of the insoluble a-
synuclein aggregates, suggesting that modulation of glucocereb-
rosidase by the chaperone might affect a-synuclein cellular
processing (Richter et al., 2014). In a different study, treatment
with the FDA-approved mucolytic ambroxol, which was previously
reported to stabilize glucocerebrosidase (Maegawa et al., 2009;
Zimran et al., 2013), reduced oxidative stress and a-synuclein
levels in an overexpressing neuroblastoma cell line (McNeill et al.,
2014).
A novel class of glucocerebrosidase non-inhibitor chaperones
has begun to emerge (Patnaik et al., 2012). Screening for
compounds that activate mutant glucocerebrosidase yielded a
series of pyrazolopyrimidine derivatives that are both biochemical
activators and chaperones of glucocerebrosidase. Some of these
compounds increased both wild-type and mutant glucocerebro-
sidase activities, as well as increased the amounts of enzyme
localized to the lysosomes in the ﬁbroblasts obtained from
Gaucher patients (Patnaik et al., 2012). A medicinal chemistry
optimized analog derived from the pyrazolopyrimidine series
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ebrosidase activity and reduce glycolipid storage in monocyte-
derived and induced pluripotent stem cell-derived macrophages
obtained from Gaucher disease patients who carry different
mutations (Aﬂaki et al., 2014). Another series of salicylic acid
derivatives has recently been demonstrated to increase glucocer-
ebrosidase activity and promote lysosomal translocation (Rogers
et al., 2012).
The non-inhibitor chaperones have a unique advantage over
existing chaperones in that they do not block the enzyme active
site; in fact, these compounds increase the enzymatic activity of
wild-type glucocerebrosidase through mechanisms still not
deﬁned. The evaluation of the effects of these compounds in
normal and disease models would be essential to deﬁne their
ability to attain the required CNS levels to achieve a therapeutic
effect. This therapeutic intervention should be amenable to PD
patients harboring a wild-type GBA1 allele. In addition, this
therapeutic approach may also extend to sporadic PD patients who
exhibit decreased glucocerebrosidase activity despite carrying two
wild-type GBA1 alleles (Gegg et al., 2012; Parnetti et al., 2014;
Schondorf et al., 2014).
7.1.4. Alternative approaches to increase lysosomal
glucocerebrosidase
7.1.4.1. Lysosomal enhancement. Lysosomal defects are clearly
associated with lysosomal storage diseases and have also been
implicated in several late onset neurodegenerative diseases,
including PD (Dehay et al., 2013; Tofaris, 2012). The lysosomal
pathway plays an important role in the maintenance of cellular
homeostasis via the degradation of bulky cytoplasmic material,
including damaged organelles and misfolded and accumulated
proteins. Genetic and experimental evidence strongly implicates
decreased lysosomal function in PD pathogenesis (Bras et al.,
2014; Dehay et al., 2010). Parkinsonism has been genetically
linked to mutations in lysosomal genes (glucocerebrosidase,
GBA1; ATPase type-13A2, ATP13A2), and lysosomal degradation
has been demonstrated to be crucial for the clearance of
aggregated a-synuclein, which represents the pathologic hall-
mark of PD (Cuervo et al., 2004; Dehay et al., 2013). The
identiﬁcation of autophagosomes and lysosomal markers as
components of the Lewy bodies in patients with sporadic PD raises
the intriguing possibility that pathogenic a-synuclein may
initially seed around impaired lysosomes and/or undegraded
autophagosomes and grow in size by the continuous deposition of
additional undegraded material as the disease progresses. In order
to reestablish the degradative homeostatic balance, several
avenues can be envisioned to effectively activate the lysosom-
al-autophagy pathway in neurons. Lentiviral-mediated CNS
expression of Beclin 1, a protein required for the initiation of
autophagosome formation, was shown to ameliorate the neuro-
degenerative pathology in a-synuclein models of PD and LBD by
inducing autophagy (Spencer et al., 2009). A different approach
involved the expression of the lysosomal-associated membrane
protein 2a (Lamp2a; Xilouri et al., 2013). Binding of substrates to
Lamp2a is the rate-limiting step for chaperone-mediated autop-
hagy. Lamp2a overexpression in different neuronal cellular
systems stimulated autophagy and selectively protected against
adenoviral-mediated wild-type a-synuclein neurotoxicity. In
addition, Lamp2a augmentation through the nigral injection of
recombinant adeno-associated virus vectors ameliorated a-
synuclein-mediated dopaminergic cell loss by increasing the
survival of neurons located in the substantia nigra as well as the
axon terminals projecting into the striatum, and these effects
were associated with a reduction in total a-synuclein levels and
related aberrant species (Xilouri et al., 2013).The identiﬁcation of a lysosomal master regulator, transcription
factor EB (TFEB), which regulates lysosomal biogenesis and
participates in macromolecule clearance, may provide a key to
extensive activation of the lysosomal system (Sardiello et al., 2009;
Settembre et al., 2013). Enhancement of TFEB function has been
demonstrated to stimulate the autophagy-lysosome pathway and
promote protein clearance and neuroprotection in mouse models
of protein misfolding and oxidative stress (Dehay et al., 2010;
Tsunemi et al., 2012). Notably, TFEB function was reported to be
deﬁcient in a rodent PD model and in human PD brains. Excess
cellular levels of a-synuclein in nigral dopamine neurons
prevented TFEB nuclear translocation and was associated to a
progressive decline in markers of lysosome function (Decressac
et al., 2013; Dehay et al., 2010; Tsunemi et al., 2012). Over-
expression of TFEB via adeno-associated virus vectors reversed the
lysosomal dysfunction and provided robust neuroprotection via
the clearance of a-synuclein oligomers (Decressac et al., 2013;
Dehay et al., 2010; Tsunemi et al., 2012). Upregulation of
glucocerebrosidase might contribute to the beneﬁcial effects of
TFEB, as this transcription factor has been reported to directly bind
to the GBA1 promoter and regulate its expression (Sardiello et al.,
2009). More recently, ZKSCAN3, a zinc ﬁnger family DNA-binding
protein, was identiﬁed as a master transcriptional repressor of
autophagy that counteracts TFEB activity (Chauhan et al., 2013).
The identiﬁcation of small molecules that are capable of
potentiating lysosomal metabolism through the activation of TFEB
or the inhibition of ZKSCAN3 would represent a particularly
attractive strategy for diseases with lysosomal deﬁcits. The
enhancement of the lysosomal function would provide relief to
the stressed autophagic mechanisms and may deliver a therapeu-
tic beneﬁt.
7.1.4.2. Trafﬁcking enhancement. Mounting evidence suggests that
endoplasmic reticulum-Golgi trafﬁcking defects may contribute to
PD pathogenesis. Mutations in VPS35 (vacuolar protein sorting 35),
a component of the retromer complex that mediates transport
between endosomes and the trans-Golgi network, have been
implicated in PD (Vilarino-Guell et al., 2011; Zimprich et al., 2011).
In addition, there is compelling evidence that a-synuclein buildup
in cells interferes with ER-to-Golgi trafﬁcking in yeast and
mammalian cells (Chung et al., 2013; Cooper et al., 2006; Gitler
et al., 2008; Thayanidhi et al., 2010). ER-to-Golgi vesicle trafﬁcking
blockade by a-synuclein impeded the maturation of several
proteins implicated in neurodegeneration, including glucocereb-
rosidase, and may contribute to the reduction in glucocerebrosi-
dase activity observed in the brains of sporadic PD patients and a-
synuclein overexpressing mice (Gegg et al., 2012; Mazzulli et al.,
2011; Sardi et al., 2013). Correspondingly, mutations in SCARB2,
which encodes a protein critical for glucocerebrosidase trafﬁcking
to the lysosomes, have been associated with synucleinopathies
(Bras et al., 2014; Do et al., 2011; Hopfner et al., 2013; Michelakakis
et al., 2012), and certain PD-causing mutations in GBA1 reportedly
increase glucocerebrosidase ER retention because of impaired
trafﬁcking (Ron and Horowitz, 2005).
Maturation of wild-type glucocerebrosidase through the ER is a
highly regulated process that requires Limp-2, speciﬁc phosphati-
dylinositol kinases and distinctive glycosylation (Jovic et al., 2012;
Reczek et al., 2007). Glucocerebrosidase ER retention by a-synuclein
or Gaucher-causing mutations has reportedly been alleviated by
several alternative approaches. For example, affecting ER calcium
homeostasis enhanced the capacity of the molecular chaperone
system to fold mutant misfolded glucocerebrosidase and increase its
lysosomal targeting (Ong et al., 2010; Wang and Segatori, 2013).
Reduction of the levels of ERdj3, an ER resident Hsp40 cochaperone
required to deliver client proteins to the heat shock protein
70 (Hsp70/BiP), increased mutant glucocerebrosidase folding and
S.P. Sardi et al. / Progress in Neurobiology 125 (2015) 47–62 57lysosomal targeting (Tan et al., 2014). Histone deacetylase (HDAC)
inhibitors and celastrol increased mutant glucocerebrosidase
maturation and lysosomal activity (Lu et al., 2011; Yang et al.,
2013, 2014b). Perturbation of the E3 ubiquitin ligase Rsp5/Nedd4
with N-arylbenzimidazole relieved a-synuclein-mediated gluco-
cerebrosidase ER retention in rat primary cortical neurons and iPSC-
derived neurons from a PD patient carrying the a-synuclein A53T
mutation (Chung et al., 2013).
These approaches provide alternative paths to increase
glucocerebrosidase activity and may therefore be beneﬁcial in
the reduction of a-synuclein toxicity and the amelioration of PD
neuropathology in patients with and without Gaucher mutations.
Future research should focus on determining the relative
contributions of these pathways in disease pathogenesis.
7.2. Substrate reduction therapy (SRT)
The only other approved therapy for Gaucher disease is an
oral, small-molecule approach referred to as substrate reduction
therapy (SRT) (Grabowski, 2008). Whereas ERT supplies the
missing deﬁcient enzyme, SRT targets the inhibition of a key
enzyme in the biosynthesis of glucosylceramide, the major
substrate of glucocerebrosidase, which therefore decreases the
buildup of toxic glycosphingolipids. N-n-butyl-1-deoxynojiri-
mycin (NB-DNJ, Miglustat) was the ﬁrst approved SRT; however,
as a result of a number of undesired side effects, it may only be
used in the treatment of type I Gaucher patients for whom
enzyme replacement therapy is unsuitable (Grabowski, 2008).
As expected, this compound reduced several glycosphingolipid
species, but unexpectedly increased the levels of glucosylcer-
amide in the brain, an effect attributed to the inhibition of the
non-lysosomal glucocerebrosidase (GBA2) (Ashe et al.; Nietupski
et al., 2012). Despite this paradoxical effect on the total lipid
levels, glucosylceramide synthase inhibitors have been demon-
strated to reduce a-synuclein aggregates in the brain of a mouse
model of Sandhoff Disease (Ashe et al., 2011) and a-synuclein
levels in the primary neurons from A53T-a-synuclein transgenic
mice through the stimulation of autophagy ﬂux (Shen et al.,
2014).
Novel glucosylceramide synthase inhibitors with better safety
proﬁles are under development. A second-generation glucosylcer-
amide synthase inhibitor, Eliglustat, has demonstrated acceptable
safety and efﬁcacy in Gaucher patients treated for 4 years (Lukina
et al., 2014). Eliglustat was recently approved by the U.S. Food and
Drug Administration for the long-term treatment of adult patients
with the Type 1 form of Gaucher disease (Poole, 2014). This
second-generation inhibitor selectively blocks glucosylceramide
synthase and has no effect on other glycosidases, including
lysosomal or cytosolic glucocerebrosidases. As expected, Eliglustat
lowers glycosphingolipid levels in animals and humans; however,
this compound is a substrate for the P-glycoprotein transporter
(MDR1), which results in poor brain distribution. Novel, speciﬁc
and potent third-generation inhibitors of glucosylceramide
synthase with good brain penetration proﬁles have demonstrated
a reduction in glycolipid substrates and a prolongation of the life
span in a neuropathic Gaucher disease mouse model (Cabrera-
Salazar et al., 2012). The in vivo effect of these glucosylceramide
synthase inhibitors on neuronal a-synuclein processing remains to
be established.
7.3. Necroptosis regulation
Non-traditional cell death mechanisms have emerged as
essential players in chronic neurodegenerative diseases (Lee
et al., 2013; Re et al., 2014; Vitner et al., 2014). The modulation
of necroptosis, a non-apoptotic form of programmed necrosis, hasrecently been described to promote survival in a genetic and
pharmacological mouse model of neuropathic Gaucher disease
(Vitner et al., 2014). The necroptosis pathway has numerous
effectors amenable to pharmacological targeting, which include
death receptors and various kinases (Vandenabeele et al., 2010).
Importantly, the absence of the receptor-interacting serine–
threonine kinase 3 (RIPK3) was sufﬁcient to display the salutary
effects on the neuropathic Gaucher animals (Vitner et al., 2014),
which suggests the therapeutic potential of RIPK3 inhibitors for
Gaucher disease. Additional research will be required to fully
understand the relevance of this pathway for Gaucher-related PD
and the potential use of RIPK3 or other necroptosis inhibitors as a
therapeutic approach for GBA1-associated PD and related synu-
cleinopathies.
8. Concluding remarks
The association between Gaucher disease and PD has received
substantial attention in recent years. Because of the wealth of basic
and clinical experience with Gaucher disease, the conﬁrmation of
the relationship between glucocerebrosidase gene mutations and
PD was received with great expectation. Since then, genetic and
experimental studies have validated glucocerebrosidase augmen-
tation in the CNS as a potential therapeutic target for synuclei-
nopathies. In addition, recent insights into the link between
glucocerebrosidase and a-synuclein have shed light into the
pathogenic mechanisms and suggest that this therapeutic inter-
vention might be beneﬁcial not only for individuals who carry
GBA1 mutations but also for patients who express GBA1 wild-type
alleles. Despite these promising advances, several mechanistic,
clinical and epidemiological issues must be further explored to
better understand the potential of the different therapeutic
interventions.
Mutations in GBA1 are the most common genetic risk factor for
the development of PD or DLB; however, the fact that only a small
subgroup of carriers ever develops the disease suggests the
presence of genetic and environmental modiﬁers. It is conceivable
that there are unidentiﬁed targets capable of rescuing the
homeostatic balance between glucocerebrosidase activity and a-
synuclein from the pathogenic feedback loop. From the clinical
perspective, large prospective longitudinal studies are warranted
to understand the natural history and to carefully deﬁne the
progression of motor and non-motor features of the disease to help
guide the initial trials in PD cohorts with and without GBA1
mutations. Similarly to other neurodegenerative diseases, early
detection of patients prior to marked irreversible neuronal loss, as
well as appropriate biomarkers to follow disease progression and
interventions will prove critical for the advancement of a
successful therapeutic strategy.
The success of developing a therapeutic strategy based on this
unanticipated link between Gaucher disease and PD will stimulate
the reevaluation of other rare diseases in the context of more
common forms of disease. Twenty years ago, the ﬁrst successful
enzyme replacement therapy was developed for treating Gaucher
disease. Today, the knowledge amassed for Gaucher disease has a
new purpose; our experiences with this rare disorder are helping
shed light on the development of therapeutics for more common
and complex sporadic forms of disease.
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